


## Curriculum Vitae

<b>Name</b>	Yap, Timothy Anthony	
<b>Current Position &amp; Affiliation</b>	<b>Medical Director,</b> Institute for Applied Cancer Science <b>Associate Director,</b> Department of Translational Research <b>Associate Professor,</b> Department of Investigational Cancer Therapeutics <b>Associate Professor,</b> Department of Thoracic/Head and Neck Medical Oncology; University of Texas MD Anderson Cancer Center	
<b>Country</b>	United States	

### Educational Background

Imperial College London, UK	BSc (1st class honors)	07/2000	Immunology and Infectious Diseases
Imperial College London, UK	MBBS	07/2002	Medicine
Royal College of Physicians, UK	MRCP (UK)	11/2005	General Internal Medicine
The Institute of Cancer Research, UK	PhD	08/2010	Molecular Pharmacology

### Professional Experience

2016 – Present **Medical Director**, Institute for Applied Cancer Science, UT MD Anderson Cancer Center

2016 – Present **Associate Professor**, Department of Investigational Cancer Therapeutics (Phase I

Program), and Department of Thoracic/Head and Neck Medical Oncology, UT MD Anderson Cancer Center

2016 – Present **Associate Director for Translational Research**, Khalifa Institute for Personalized Cancer Therapy, UT MD Anderson Cancer Center

## Professional Organizations

AACR, ASCO, ESMO, NRG, SWOG

## Main Scientific Publications

### Peer-Reviewed Original Research Articles

1. Hawkey CR, **Yap TA**, Pereira J, Moore DA, Davidson RN, Pasvol G, Kon OM, Wall RA, Wilkinson RJ. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. *Clinical Infectious Diseases* 40(9):1368-71, 5/2005.
2. Vidal L, **Yap TA**, White CL, Twigger K, Hingorani M, Kaye SB, Harrington KJ, de Bono JS. Reovirus and Oncolytic Viruses for the Targeted Treatment of Cancer. *Targeted Oncology* 1(3):130-150, 5/2006.
3. **Yap TA**, Eisen TG. Adjuvant therapy of renal cell carcinoma. *Clin Genitourin Cancer* 5(2):120-30, 9/2006. PMID: 17026800.
4. **Yap TA**, Molife LR, Blagden SP, de Bono S. Targeting cell cycle kinases and kinesins in anticancer drug development. *Expert Opin Drug Discov* 2(4):539-60, 4/2007. PMID: 23484760.
5. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, **Yap TA**, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. *Clin Cancer Res* 13(19):5834-40, 10/2007. PMID: 17908976.
6. **Yap TA**, Carden CP, Attard G, de Bono JS. Targeting CYP17: established and novel approaches in prostate cancer. *Curr Opin Pharmacol* 8(4):449-57, 8/2008. e-Pub 7/2008. PMID: 18619560.
7. **Yap TA**, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. *Curr Opin Pharmacol* 8(4):393-412, 8/2008. e-Pub 8/2008. PMID: 18721898.
8. Attard G, Reid AH, **Yap TA**, Raynaud F, Dowsett M, Settatee S, Barrett M, Parker C, Martins V, Folkard E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. *J Clin Oncol* 26(28):4563-71, 10/2008. e-Pub 7/2008. PMID: 18645193.
9. Vidal L, Pandha HS, **Yap TA**, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ, DeBono JS. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. *Clin Cancer Res* 14(21):7127-37, 11/2008. PMID: 18981012.

10. **Yap TA**, Brunetto A, Pandha H, Harrington K, Debono JS. Reovirus therapy in cancer: has the orphan virus found a home? *Expert Opin Investig Drugs* 17(12):1925-35, 12/2008. PMID: 19012507.
11. Rasheed S, **Yap TA**, Zia A, McDonald PJ, Glynne-Jones R. Chemoradiotherapy – an alternative to surgery for squamous cell carcinoma of the rectum. Report of six cases and literature review. *Colorectal Disease* 11(2):191-7, 2/2009.
12. **Yap TA**, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. *Nat Rev Cancer* 9(3):167-81, 3/2009. PMID: 19238149.
13. Fong PC, Boss DS, **Yap TA**, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med* 361(2):123-34, 7/2009. e-Pub 6/2009. PMID: 19553641.
14. Sarker D, Reid AH, **Yap TA**, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. *Clin Cancer Res* 15(15):4799-805, 8/2009. e-Pub 7/2009. PMID: 19638457.
15. **Yap TA**, Kaye SB, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in BRCA mutation carriers. *The New England Journal of Medicine* 361(17):1707-1708, 10/2009.
16. Sandhu SK, **Yap TA**, de Bono JS. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. *Eur J Cancer* 46(1):9-20, 1/2010. PMID: 19926276.
17. Carden CP, Sarker D, Postel-Vinay S, **Yap TA**, Attard G, Banerji U, Garrett MD, Thomas GV, Workman P, Kaye SB, de Bono JS. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? *Drug Discov Today* 15(3-4):88-97, 2/2010. e-Pub 12/2009. PMID: 19961955.
18. Grimshaw KM, Hunter LJ, **Yap TA**, Heaton SP, Walton MI, Woodhead SJ, Fazal L, Reule M, Davies TG, Seavers LC, Lock V, Lyons JF, Thompson NT, Workman P, Garrett MD. AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth. *Mol Cancer Ther* 9(5):1100-10, 5/2010. e-Pub 4/2010. PMCID: PMC4825853.
19. Gourley C, Michie CO, Roxburgh P, **Yap TA**, Harden S, Paul J, Ragupathy K, Todd R, Petty R, Reed N, Hayward RL, Mitchell P, Rye T, Schellens JH, Lubinski J, Carmichael J, Kaye SB, Mackean M, Ferguson M. Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. *Journal of Clinical Oncology* 28(15):2505-11, 5/2010. e-Pub 4/2010. PMID: 20406939.
20. Fong PC\*, **Yap TA\***, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB. Poly(ADP)-ribose

- polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. *Journal of Clinical Oncology* 28(15):2512-9, 5/2010. PMID: 20406929. \*Joint 1<sup>st</sup> authors.
21. **Yap TA**, de Bono JS. Targeting the HGF/c-Met axis: state of play. *Mol Cancer Ther* 9(5):1077-9, 5/2010. e-Pub 5/2010. PMID: 20442310.
  22. **Yap TA**, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. *Nat Rev Cancer* 10(7):514-23, 7/2010. e-Pub 6/2010. PMID: 20535131.
  23. Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, **Yap TA**, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, Leitzel K, Gualberto A, de Bono JS. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. *Br J Cancer* 103(3):332-9, 7/2010. e-Pub 7/2010. PMCID: PMC2920021.
  24. Carden CP, **Yap TA**, Kaye SB. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. *Curr Opin Oncol* 22(5):473-80, 9/2010. PMID: 20485165.
  25. **Yap TA**, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. *Journal of Clinical Oncology* 28(25):3965-72, 9/2010. PMID: 20679611.
  26. Brunetto AT, Ang JE, Olmos D, Tan D, Barriuso J, Arkenau HT, **Yap TA**, Molife LR, Banerji U, de Bono J, Judson I, Kaye S. A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition. *Eur J Cancer* 46(15):2739-45, 10/2010. e-Pub 8/2010. PMID: 20667711.
  27. **Yap TA**, de Bono JS, Kaye SB, Tutt A, Ashworth A, Schellens JHM. BRCA1 CpG Island Hypermethylation Predicts Sensitivity to PARP Inhibitors. *Journal of Clinical Oncology* 28(29):e565-6, 10/2010.
  28. **Yap TA**, Sandhu SK, Carden CP, de Bono JS. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. *CA Cancer J Clin* 61(1):31-49, Jan-Feb, 1/2011. e-Pub 1/2011. PMID: 21205831.
  29. **Yap TA**, Walton MI, Hunter LJ, Valenti M, de Haven Brandon A, Eve PD, Ruddle R, Heaton SP, Henley A, Pickard L, Vijayaraghavan G, Caldwell JJ, Thompson NT, Aherne W, Raynaud FI, Eccles SA, Workman P, Collins I, Garrett MD. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930. *Mol Cancer Ther* 10(2):360-71, 2/2011. e-Pub 12/2010. PMCID: PMC4944842.
  30. **Yap TA**, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, Pope L, Clark J, Futreal A, Germuska M, Collins D, deSouza NM, Leach MO, Savage



- RE, Waghorne C, Chai F, Garmey E, Schwartz B, Kaye SB, de Bono JS. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. *Journal of Clinical Oncology* 29(10):1271-9, 4/2011. e-Pub 3/2011. PMID: 21383285.
31. Olmos D, Barker D, Sharma R, Brunetto AT, **Yap TA**, Taegtmeier AB, Barriuso J, Medani H, Degenhardt YY, Allred AJ, Smith DA, Murray SC, Lampkin TA, Dar MM, Wilson R, de Bono JS, Blagden SP. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. *Clin Cancer Res* 17(10):3420-30, 5/2011. e-Pub 4/2011. PMID: 21459796.
  32. Brunetto A, Olmos D, Arkenau HT, Tan D, **Yap TA**, de Bono J, Barriuso J, Kaye S. Perceptions and referral trends into phase I oncology trials: results of a clinical survey. *Journal of Oncology* 2011, 6/2011.
  33. Olmos D, Baird RD, **Yap TA**, Massard C, Pope L, Sandhu SK, Attard G, Dukes J, Papadatos-Pastos D, Grainger P, Kaye SB, de Bono JS. Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. *Clin Cancer Res* 17(15):5188-96, 8/2011. e-Pub 4/2011. PMID: 21531820.
  34. **Yap TA**, Zivi A, Omlin A, de Bono JS. The changing therapeutic landscape of castration-resistant prostate cancer. *Nat Rev Clin Oncol* 8(10):597-610, 8/2011. e-Pub 8/2011. PMID: 21826082.
  35. **Yap TA**, Olmos D, Molife LR, de Bono JS. Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. *Expert Opin Investig Drugs* 20(9):1293-304, 9/2011. e-Pub 7/2011. PMID: 21777167.
  36. de Bono JS and **Yap TA**. c-MET: an exciting new target for anticancer therapy. *Ther Adv Med Oncol* 3(1 Suppl):S3-5, 11/2011. PMCID: PMC3225019.
  37. de Bono JS and **Yap TA**. Future directions in the evaluation of c-MET-driven malignancies. *Ther Adv Med Oncol* 3(1 Suppl):S51-60, 11/2011. PMCID: PMC3225021.
  38. **Yap TA**, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. *Journal of Clinical Oncology* 29(35):4688-95, 12/2011. PMID: 22025163.
  39. **Yap TA**, Sandhu SK, Alam SM, de Bono JS. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine. *Curr Drug Targets* 12(14):2045-58, 12/2011. PMID: 21777195.
  40. Sandhu SK, **Yap TA**, de Bono JS. The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment. *Curr Drug Targets* 12(14):2034-44, 12/2011. PMID: 21777194.

41. **Yap TA**, Swanton C, de Bono JS. Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon? *EPMA J* 3(1):3, 1/2012. e-Pub 1/2012. PMID: PMC3375104.
42. **Yap TA**, Gerlinger M, Futreal PA, Puztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. *Sci Transl Med* 4(127):127ps10, 3/2012. PMID: 22461637.
43. **Yap TA**, Cortes-Funes H, Shaw H, Rodriguez R, Olmos D, Lal R, Fong PC, Tan DS, Harris D, Capdevila J, Coronado C, Alfaro V, Soto-Matos A, Fernández-Teruel C, Siguero M, Tabernero JM, Paz-Ares L, de Bono JS, López-Martin JA. First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours. *Br J Cancer* 106(8):1379-85, 4/2012. PMID: PMC3326684.
44. Arkenau HT, Plummer R, Molife LR, Olmos D, **Yap TA**, Squires M, Lewis S, Lock V, Yule M, Lyons J, Calvert H, Judson I. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. *Ann Oncol* 23(5):1307-13, 5/2012. e-Pub 10/2011. PMID: 22015452.
45. Basu B, **Yap TA**, Molife LR, de Bono JS. Targeting the DNA damage response in oncology: past, present and future perspectives. *Curr Opin Oncol* 24(3):316-24, 5/2012. PMID: 22476188.
46. **Yap TA**, Walton MI, Grimshaw KM, Te Poele RH, Eve PD, Valenti MR, de Haven Brandon AK, Martins V, Zetterlund A, Heaton SP, Heinzmann K, Jones PS, Feltell RE, Reule M, Woodhead SJ, Davies TG, Lyons JF, Raynaud FI, Eccles SA, Workman P, Thompson NT, Garrett MD. AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. *Clin Cancer Res* 18(14):3912-23, 7/2012. e-Pub 7/2012. PMID: 22781553.
47. **Yap TA**, Pezaro CJ, de Bono JS. Cabazitaxel in metastatic castration-resistant prostate cancer. *Expert Rev Anticancer Ther* 12(9):1129-36, 9/2012. PMID: 23098113.
48. **Yap TA**, Workman P. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. *Annu Rev Pharmacol Toxicol* 52:549-73, 2012. PMID: 22235862.
49. Perkins G, **Yap TA**, Pope L, Cassidy AM, Dukes JP, Riisnaes R, Massard C, Cassier PA, Miranda S, Clark J, Denholm KA, Thway K, Gonzalez De Castro D, Attard G, Molife LR, Kaye SB, Banerji U, de Bono JS. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. *PLoS One* 7(11):e47020, 2012. e-Pub 11/2012. PMID: PMC3492590.
50. Vitfell-Pedersen J, **Yap TA**, Moreno V, Baird RD, Khan AZ, Barton DP, Kaye SB. The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials. *Eur J Gynaecol Oncol* 33(2):211-3, 2012. PMID: 22611966.

51. **Yap TA**, Arkenau HT, Camidge DR, George S, Serkova NJ, Gwyther SJ, Spratlin JL, Lal R, Spicer J, Desouza NM, Leach MO, Chick J, Poondru S, Boinpally R, Gedrich R, Brock K, Stephens A, Eckhardt SG, Kaye SB, Demetri G, Scurr M. First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. *Clin Cancer Res* 19(4):909-19, 2/2013. PMID: PMC3880798.
52. **Yap TA**, Omlin A, de Bono JS. Development of therapeutic combinations targeting major cancer signaling pathways. *Journal of Clinical Oncology* 31(12):1592-605, 4/2013. e-Pub 3/2013. PMID: 23509311.
53. Tan DS, **Yap TA**, Hutka M, Roxburgh P, Ang J, Banerjee S, Grzybowska E, Gourley C, Gore ME, Kaye SB. Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. *Eur J Cancer* 49(6):1246-53, 4/2013. e-Pub 12/2012. PMID: 23265709.
54. Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, **Yap TA**, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. *Ann Oncol* 24(5):1416-8, 5/2013. e-Pub 3/2013. PMID: 23524863.
55. Khan KH, **Yap TA**, Yan L, Cunningham D. Targeting the PI3K-AKT-mTOR signaling network in cancer. *Chin J Cancer* 32(5):253-65, 5/2013. PMID: PMC3845556.
56. Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, **Yap TA**, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. *Clin Cancer Res* 19(19):5485-93, 10/2013. e-Pub 8/2013. PMID: 23922302.
57. **Yap TA**, Popat S. The role of afatinib in the management of non-small cell lung carcinoma. *Expert Opin Drug Metab Toxicol* 9(11):1529-39, 11/2013. e-Pub 8/2013. PMID: 23985030.
58. **Yap TA**, Lorente D, Omlin A, Olmos D, de Bono JS. Circulating tumor cells: a multifunctional biomarker. *Clin Cancer Res* 20(10):2553-68, 5/2014. PMID: 24831278.
59. Ong M, Carreira S, Goodall J, Mateo J, Figueiredo I, Rodrigues DN, Perkins G, Seed G and **Yap TA**, Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. *Br J Cancer* 111(5):828-36, 8/2014. e-Pub 7/2014. PMID: PMC4150267.
60. Smith AD, Roda D and **Yap TA**. Strategies for modern biomarker and drug development in oncology. *J Hematol Oncol* 7:70, 10/2014. e-Pub 10/2014. PMID: PMC4189730.

61. **Yap TA**, Yan L, Patnaik A, Tunariu N, Biondo A, Fearen I, Papadopoulos KP, Olmos D, Baird R, Delgado L, Tetteh E, Beckman RA, Lupinacci L, Riisnaes R, Decordova S, Heaton SP, Swales K, deSouza NM, Leach MO, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. *Clin Cancer Res* 20(22):5672-85, 11/2014. e-Pub 9/2014. PMID: PMC4233149.
62. **Yap TA**, Popat S. Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. *Pharmgenomics Pers Med* 7:285-95, 2014. e-Pub 9/2014. PMID: PMC4178554.
63. **Yap TA**. Challenges in combining novel molecularly targeted agents in cancer medicine. *Ann Oncol* 26(1):9-11, 1/2015. e-Pub 10/2014. PMID: 25336115.
64. Papadatos-Pastos D, De Miguel Luken MJ and **Yap TA**. Combining targeted therapeutics in the era of precision medicine. *Br J Cancer* 112(1):1-3, 1/2015. PMID: PMC4453608.
65. Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, **Yap TA**, Yan L, de Bono JS. Antitumor activity in RAS-driven tumors by blocking AKT and MEK. *Clin Cancer Res* 21(4):739-48, 2/2015. e-Pub 12/2014. PMID: PMC4335074.
66. Rafii S, Roda D, Geuna E, Jimenez B, Rihawi K, Capelan M, **Yap TA**, Molife LR, Kaye SB, de Bono JS, Banerji U. Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. *Clin Cancer Res* 21(8):1869-76, 4/2015. e-Pub 2/2015. PMID: PMC4401558.
67. **Yap TA**, Bjerke L, Clarke PA, Workman P. Drugging PI3K in cancer: refining targets and therapeutic strategies. *Curr Opin Pharmacol* 23:98-107, 8/2015. e-Pub 6/2015. PMID: PMC4728196.
68. Frenel JS, Carreira S, Goodall J, Roda D, Perez-Lopez R, Tunariu N, Riisnaes R, Miranda S, Figueiredo I, Nava-Rodrigues D, Smith A, Leux C, Garcia-Murillas I, Ferraldeschi R, Lorente D, Mateo J, Ong M, **Yap TA**, Banerji U, Gasi Tandefelt D, Turner N, Attard G, de Bono JS. Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. *Clin Cancer Res* 21(20):4586-96, 10/2015. e-Pub 6/2015. PMID: PMC4580992.
69. Abdelraouf F, Sharp A, Maurya M, Mair D, Wotherspoon A, Leary A, Gonzalez de Castro D, Bhosle J, Nassef A, Gaafar T, Popat S, **Yap TA**, O'Brien M. Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice. *BMC Res Notes* 8:688, 11/2015. e-Pub 11/2015. PMID: PMC4652351.



70. Geuna E, Roda D, Rafii S, Jimenez B, Capelan M, Rihawi K, Montemurro F, **Yap TA**, Kaye SB, De Bono JS, Molife LR, Banerji U. Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. *Br J Cancer* 113(11):1541-7, 12/2015. e-Pub 11/2015. PMID: PMC4705886.
71. Lopez J, Harris S, Roda D and **Yap TA**. Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. *Transl Oncogenomics* 7(Suppl 1):1-11, 2015. e-Pub 11/2015. PMID: PMC4648610.
72. Kumar R, Lu SK, Minchom A, Sharp A, Davidson M, Gunapala R, **Yap TA**, Bhosle J, Popat S, O'Brien ME. A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. *Cancer Chemother Pharmacol* 77(2):375-83, 2/2016. e-Pub 12/2015. PMID: 26706729.
73. Khan KH, **Yap TA**, Ring A, Molife LR, Bodla S, Thomas K, Zivi A, Smith A, Judson I, Banerji U, de Bono JS, Kaye SB. Phase I trial outcomes in older patients with advanced solid tumours. *Br J Cancer* 114(3):262-8, 2/2016. e-Pub 1/2016. PMID: PMC4742590.
74. **Yap TA**, Gillespie L, Ellison S, Flechas SV, Koo MS, Martinez AE, Vredenburg VT. Invasion of the Fungal Pathogen *Batrachochytrium dendrobatidis* on California Islands. *Ecohealth* 13(1):145-50, 3/2016. e-Pub 10/2015. PMID: 26493624.
75. Brown JS, Kaye SB and **Yap TA**. PARP inhibitors: the race is on. *Br J Cancer* 114(7):713-5, 3/2016. PMID: PMC4984871.
76. Weller A, O'Brien MER, Ahmed M, Popat S, Bhosle J, McDonald F, **Yap TA**, Du Y, Vlahos I, deSouza NM. Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer. *Eur J Cancer* 59:65-78, 5/2016. e-Pub 3/2016. PMID: 27016624.
77. Sharp A, Bhosle J, Abdelraouf F, Popat S, O'Brien M and **Yap TA**. Development of molecularly targeted agents and immunotherapies in small cell lung cancer. *Eur J Cancer* 60:26-39, 6/2016. e-Pub 4/2016. PMID: 27060747.
78. Harris SJ, Brown J, Lopez J and **Yap TA**. Immuno-oncology combinations: raising the tail of the survival curve. *Cancer Biol Med* 13(2):171-93, 6/2016. PMID: PMC4944548.
79. **Yap TA**, Banerji U, de Bono JS, Workman P. Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development. *Journal of Clinical Oncology* 34(20):2431-2, 7/2016. e-Pub 5/2016. PMID: 27138581.
80. Lim JS, Turner NC and **Yap TA**. CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer. *Cancer Discov* 6(7):697-9, 7/2016. PMID: 27371575.
81. **Yap TA**, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P, de Bono JS. Drug discovery in advanced prostate cancer: translating biology into therapy. *Nat Rev Drug Discov* 15(10):699-718, 10/2016. e-Pub 7/2016. PMID: 27444228.

82. Lim JS, Collins D and **Yap TA**. Emerging strategies for the treatment of advanced small cell lung cancer. *J Thorac Dis* 8(10):E1249-E1253, 10/2016. PMID: PMC5107470.
83. Dolly SO, Kalaitzaki E, Puglisi M, Stimpson S, Hanwell J, Fandos SS, Stapleton S, Ansari T, Peckitt C, Kaye S, Lopez J, **Yap TA**, van der Graaf W, de Bono J, Banerji U. A study of motivations and expectations of patients seen in phase 1 oncology clinics. *Cancer* 122(22):3501-3508, 11/2016. e-Pub 9/2016. PMID: PMC5111585.
84. Puglisi M, Stewart A, Thavasulu P, Frow M, Carreira S, Minchom A, Punwani R, Bhosle J, Popat S, Ratoff J, de Bono J, **Yap TA**, O'Brien M, Banerji U. Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions. *Oncology* 90(5):280-8, 2016. e-Pub 4/2016. PMID: 27082424.
85. **Yap TA**, Macklin-Doherty A, Popat S. Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. *Eur J Cancer* 70:12-21, 1/2017. e-Pub 11/2016. PMID: 27866095.
86. Lim JS, Sundar R, Chénard-Poirier M, Lopez J and **Yap TA**. Emerging biomarkers for PD-1 pathway cancer therapy. *Biomark Med* 11(1):53-67, 1/2017. e-Pub 12/2016. PMID: 27936870.
87. Brown JS, O'Carrigan B, Jackson SP and **Yap TA**. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. *Cancer Discov* 7(1):20-37, 1/2017. e-Pub 12/2016. PMID: PMC5300099.
88. **Yap TA**, Popat S. Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match? *J Thorac Oncol* 12(1):12-14, 1/2017. PMID: 27988098.
89. Collins DC, Sundar R, Lim JSJ and **Yap TA**. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. *Trends Pharmacol Sci* 38(1):25-40, 1/2017. e-Pub 11/2016. PMID: 27871777.
90. Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O'Brien ME and **Yap TA**. Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit. *Eur J Cancer* 75:56-62. e-Pub 2/2017. PMID: 28214659.
91. George A, Kristeleit R, Ruffi S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB and **Yap TA**. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. *Eur J Cancer* 76:52-59. e-Pub 3/2017. PMID: 28273485.
92. Sundar R, Valeri N, Harrington KJ and **Yap TA**. Combining Molecularly Targeted Agents: Is More Always Better? *Clin Cancer Res* 23(5):1123-1125, 3/2017. e-Pub 11/2016. PMID: 27836864.
93. Winfield JM, Tunariu N, Rata M, Miyazaki K, Jerome NP, Germuska M, Blackledge MD, Collins DJ, de Bono JS, **Yap TA**, deSouza NM, Doran SJ, Koh

- DM, Leach MO, Messiou C, Orton MR. Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging. *Radiology*:161965. e-Pub 3/2017. PMID: 28301311.
94. Kumar R, Collins D, Dolly S, McDonald F, O'Brien MER and **Yap TA**. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. *Curr Probl Cancer* 41(2):111-124, Mar - Apr, 3/2017. e-Pub 12/2016. PMID: 28214087.
95. Dolly SO, Collins DC, Sundar R, Popat S and **Yap TA**. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. *Drugs*. e-Pub 4/2017. PMID: 28378229.
96. Saeed R, Gourley C, Rajiv K, Geuna E, Ang JE, Rye T, Chen L, Shapira-Frommer R, Friedlanders M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB and **Yap TA**. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. *Oncotarget*. e-Pub 4/2017.
97. Lim JSJ, Janku F and **Yap TA**. Circulating tumor DNA - from bench to bedside. *Curr Probl Cancer* 41(3):212-221, May - Jun, 5/2017. e-Pub 3/2017. PMID: 28416241.
98. Takebe N and **Yap TA**. Precision Medicine in Oncology. *Curr Probl Cancer* 41(3):163-165, May - Jun, 5/2017. e-Pub 1/2017. PMID: 28372822.
99. Sundar R, Hong DS, Kopetz S and **Yap TA**. Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. *Cancer Discov* 7(6):558-560, 6/2017. PMID: PMC5458523.
100. **Yap TA**, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. *Nat Rev Cancer* 17(8):475-488, 7/2017. PMID: 28740119.
101. Sundar R, Brown J, Ingles Russo A and **Yap TA**. Targeting ATR in cancer medicine. *Curr Probl Cancer* 41(4):302-315, Jul - Aug, 7/2017. e-Pub 5/2017. PMID: 28662958.
102. Capelan M, Roda D, Geuna E, Rihawi K, Bodla S, Kaye SB, Bhosle J, Banerji U, O'Brien M, de Bono JS, Popat S and **Yap TA**. Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt? *Lung Cancer* 111:6-11, 9/2017. e-Pub 6/2017. PMID: 28838399.
103. Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, **Yap TA**, Tripathy D, Mills GB, Meric-Bernstam F. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. *Clin Cancer Res* 23(21):6468-6477, 11/2017. PMID: PMC5679124.
104. Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N and **Yap TA**. High frequency of radiological differential responses with poly(ADP-Ribose)

- polymerase (PARP) inhibitor therapy. *Oncotarget* 8(61):104430-104443, 11/2017. e-Pub 11/2017. PMID: PMC5732817.
105. Vishwanathan K, Dickinson PA, Bui K, Cassier PA, Greystoke A, Lisbon E, Moreno V, So K, Thomas K, Weilert D, **Yap TA**, Plummer R. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers. *J Clin Pharmacol*. e-Pub 11/2017. PMID: 29178442.
  106. **Yap TA**, Rodon J. Development of Molecularly Driven Targeted Combination Strategies. *Oncologist* 22(12):1421-1423, 12/2017. e-Pub 10/2017. PMID: PMC5728037.
  107. Pilié PG, LoRusso PM and **Yap TA**. Precision Medicine: Progress, Pitfalls, and Promises. *Mol Cancer Ther* 16(12):2641-2644, 12/2017. PMID: 29203693.
  108. Minchom A, Thavasu P, Ahmad Z, Stewart A, Georgiou A, O'Brien MER, Popat S, Bhosle J, **Yap TA**, de Bono J, Banerji U. A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. *PLoS One* 12(10):e0186106, 2017. e-Pub 10/2017. PMID: PMC5628934.
  109. Sundar R, Chénard-Poirier M, Collins DC and **Yap TA**. Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. *Front Med (Lausanne)* 4:39, 2017. e-Pub 4/2017. PMID: PMC5385461.
  110. Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, **Yap TA**, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. *Cancer Cell* 33(3):401-416.e8, 3/2018. PMID: PMC5944839.
  111. Lam M, Pant S and **Yap TA**. Combination drug development in BRAF mutant colorectal cancer. *Oncoscience* 5(3-4):51-53, 3/2018. e-Pub 4/2018. PMID: PMC5978439.
  112. Subbiah V, Rodon J and **Yap TA**. Precision oncology: East meets West. *Int J Cancer* 142(9):1734-1737, 5/2018. e-Pub 1/2018. PMID: 29243227.
  113. Janku F, **Yap TA**, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? *Nat Rev Clin Oncol* 15(5):273-291, 5/2018. e-Pub 3/2018. PMID: 29508857.
  114. Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, **Yap TA**, Wang F, Chen K, Salgia R, Hong D. Untying the gordian knot of targeting MET in cancer. *Cancer Treat Rev* 66:95-103, 5/2018. e-Pub 4/2018. PMID: 29730462.
  115. Kurnit KC, Dumbrava EEI, Litzemberger B, Khotskaya YB, Johnson AM, **Yap TA**, Rodon J, Zeng J, Shufean MA, Bailey AM, Sánchez NS, Holla V, Mendelsohn J, Shaw KM, Bernstam EV, Mills GB, Meric-Bernstam F. Precision Oncology Decision Support: Current Approaches and Strategies for the Future. *Clin Cancer Res* 24(12):2719-2731, 6/2018. e-Pub 2/2018. PMID: PMC6004235.



116. O'Brien MER, Sarker D, Bhosle J, Thillai K, **Yap TA**, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J, Spicer J. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. e-Pub 8/2018. PMID: 30088048.
117. Ileana Dumbrava E, Meric-Bernstam F and **Yap TA**. Challenges with biomarkers in cancer drug discovery and development. *Expert Opin Drug Discov* 13(8):1-6, 8/2018. e-Pub 5/2018. PMID: 29792354.
118. Tang C, Jiang W and **Yap TA**. Efficacy and Toxic Effects of Cancer Immunotherapy Combinations-A Double-Edged Sword. *JAMA Oncol* 4(8):1116-1117, 8/2018. e-Pub 1/2018. PMID: 29327039.
119. Ileana Dumbrava EE, Mills GB and **Yap TA**. Targeting gamma secretase: has progress moved up a notch? *Ann Oncol* 29(9):1889-1891, 9/2018. e-Pub 8/2018. PMID: 30084907.
120. Al-Saffar NMS, Troy H, Wong Te Fong AC, Paravati R, Jackson LE, Gowan S, Boulton JKR, Robinson SP, Eccles SA, **Yap TA**, Leach MO, Chung YL. Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma. *Br J Cancer* 119(9):1118-1128, 10/2018. e-Pub 10/2018. PMID: 30377337.
121. O'Carrigan B, Lim JSJ, Jalil A, Harris SJ, Papadatos-Pastos D, Banerji U, Lopez J, de Bono JS and **Yap TA**. Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre. *Br J Cancer* 119(8):922-927, 10/2018. e-Pub 10/2018. PMID: 30318518.
122. Stewart RA, Pilié PG and **Yap TA**. Development of PARP and Immune-Checkpoint Inhibitor Combinations. *Cancer Res* 78(24):6717-6725, 12/2018. e-Pub 11/2018. PMID: 30498083.
123. Janku F, Hess KR and **Yap TA**. Moving Precision Oncology Forward Amid Myths and Misconceptions. *JAMA Oncol* 4(12):1788-1789, 12/2018. PMID: 30419079.
124. Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, **Yap TA**, Mills GB, Peng G. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. *Cancer Res* 79(2):311-319, 1/2019. e-Pub 11/2018. PMID: PMC6588002.
125. **Yap TA**, Plummer R, Azad NS, Helleday T. The DNA Damaging Revolution: PARP Inhibitors and Beyond. *Am Soc Clin Oncol Educ Book* 39:185-195, 1/2019. e-Pub 5/2019. PMID: 31099635.
126. Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, **Yap TA**, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL. Seamless Designs: Current Practice and Considerations for Early-Phase Drug

- Development in Oncology. *J Natl Cancer Inst* 111(2):118-128, 2/2019. e-Pub 12/2018. PMID: PMC6376915.
127. Pilié PG, Tang C, Mills GB and **Yap TA**. State-of-the-art strategies for targeting the DNA damage response in cancer. *Nat Rev Clin Oncol* 16(2):81-104, 2/2019. e-Pub 10/2018. PMID: 30356138.
128. George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, **Yap TA**, Cleeland CS, Hong DS. Improving attribution of adverse events in oncology clinical trials. *Cancer Treat Rev* 76:33-40, 6/2019. e-Pub 4/2019. PMID: 31108240.
129. Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, **Yap TA**, Mills GB. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. *Cancer Cell* 35(6):851-867.e7, 6/2019. PMID: PMC6642675.
130. Pilié PG, Gay CM, Byers LA, O'Connor MJ and **Yap TA**. PARP Inhibitors: Extending Benefit Beyond BRCA Mutant Cancers. *Clin Cancer Res* 25(13):3759-3771, 7/2019. e-Pub 2/2019. PMID: 30760478.
131. Pant S, Maitra A and **Yap TA**. PARP inhibition - opportunities in pancreatic cancer. *Nature Reviews Clinical Oncology* 16(10):595-596, 10/2019. PMID: 31332344.
132. **Yap TA**, Winter JN, Giulino-Roth L, Longley J, Lopez J, Michot JM, Leonard JP, Ribrag V, McCabe MT, Creasy CL, Stern M, Pene Dumitrescu T, Wang X, Frey S, Carver J, Horner T, Oh C, Khaled A, Dhar A, Johnson PWM. Phase 1 study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematological and solid tumors. *Clin Cancer Res* 25(24):7331-7339, 12/2019. e-Pub 8/2019. PMID: 31471312.
133. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, **Yap TA**, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. *Journal for ImmunoTherapy of Cancer*, 3/2020. PMID: 32188704.
134. **Yap TA**, O'Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, Tunariu N, Perez-Lopez R, Rodrigues DN, Riisnaes R, Figueiredo I, Carreira S, Hare B, McDermott K, Khalique S, Williamson CT, Natrajan R, Pettitt SJ, Lord CJ, Banerji U, Pollard J, Lopez J, de Bono JS. Phase I Trial of First-in-Class

- ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. *Journal of Clinical Oncology*, 6/2020. PMID: 32568634.
135. **Yap TA**, Kristeleit R, Michaelarea V, Pettitt SJ, Lim JSJ, Carreira S, Roda D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Nava Rodrigues D, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner NC, Ruddle R, Raynaud FI, Decordova SA, Swales KE, Finneran L, Hall E, Rugman P, Lindemann JPO, Foxley A, Lord CJ, Banerji U, Plummer R, Basu B, Lopez JS, Drew Y, de Bono JS. Phase I trial of the poly(ADP-ribose)Timothy A. Yap, MBBS, PhD, FRCP Page 17 of 46 polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers. *Cancer Discovery*, 6/2020.
136. Frumovitz M, Westin SN, Salvo G, Zarifa A, Xu M, **Yap TA**, Rodon AJ, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. *Gynecology Oncology*, 6/2020. PMID: 32534809.
137. Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, Forster M, Farley A, Wherton D, Mehmi M, Sharpe R, Mills TC, Cerone MA, **Yap TA**, Watkins TBK, Lim E, Swanton C, Billingham L. The National Lung Matrix Trial of personalized therapy in lung cancer. *Nature*, 7/2020. PMID: 32669708.
138. **Yap TA**, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris N, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors. *Cancer Discovery*, 9/2020. PMID: 32988960.
139. Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, Forster M, Farley A, Wherton D, Mehmi M, Sharpe R, Mills TC, Cerone MA, **Yap TA**, Watkins TBK, Lim E, Swanton C, Billingham L. Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer. *Nature* 585(7826):E21, 9/2020. PMID: 32887973.
140. Pascual J, Lim JSJ, Macpherson IRJ, Armstrong AC, Ring A, Okines AF, Cutts RJ, Herrera-Abreu MT, Garcia-Murillas I, Pearson A, Hrebien S, Gevensleben H, Proszek PZ, HUBank M, Hills M, King J, Parmar M, Prout T, Finneran L, Malia J, Swales KE, Ruddle R, Raynaud FI, Turner A, Hall E, **Yap TA**, Lopez JS, Turner NC. Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers. *Cancer Discovery*, 9/2020. PMID: 32958578.

141. Pettitt SJ, Frankum JR, Punta M, Lise S, Alexander J, Chen Y, **Yap TA**, Haider S, Tutt ANJ, Lord CJ. Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. *Cancer Discov* 10(10):1475-1488, 10/2020. e-Pub 7/2020. PMID: 32699032.
142. Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, **Yap TA**, Jankku F, Tsimberisou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. *J Immunother Cancer* 8(2):e000931, 10/2020. PMCID: PMC7590372.
143. **Yap TA**, Kristeleit R, Michalarea V, Pettitt SJ, Lim JSJ, Carreira S, Roda D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Rodriguez DN, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner NC, Ruddle R, Raynaud FI, Decordova S, Swales KE, Finneran L, Hall E, Rugman P, Lindemann JPO, Fozley A, Lord CJ, Banerji U, Plummer R, Basu B, Lopez JS, Drew Y, de Bono JS. Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non- BRCA1/2-Mutant Cancers. *Cancer Discov* 10(10):1528-1543, 10/2020. PMID: 3253274.
144. Wang L, Yang L, Wang C, Zhao W, Ju Z, Zhang W, Shen J, Peng Y, An C, Luu YT, Song S, **Yap TA**, Ajani JA, Mills GB, Shen X, Peng G. Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. *J Clin Invest* 130(11):5951-5966, 11/2020. PMCID: PMC7598069.
145. Patnaik A, **Yap TA**, Chung HC, de Miguel M, Bang Y, Lin C, Su W, Italiano A, Hoong Chow K, Szpurka AM, Yu D, Zhao Y, Carlsen M, Schmidt S, Vangerow B, Gandhi L, Xu X, Bendell JC. Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial. *Clin Cancer Res*, 11/2020. PMID: 33229456.
146. Hahn AW, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, **Yap T**, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. *ESMO Open* 5(6):e001073, 11/2020. PMCID: PMC7684827.
147. Abdel-Wahab R, **Yap TA**, Madison R, Pant S, Cooke M, Wang K, Zhao H, Bekaii-Saab T, Karatas E, Kwong LN, Meric-Bernstam F, Borad M, Javle M. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. *Sci Rep* 10(1):22087, 12/2020. PMID: 33328484.
148. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Jankku F, Pant S, **Yap TA**, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular profiling of metastatic bladder cancer



- early-phase clinical trial participants predicts patient outcomes. *Mol Cancer Res*, 12/2020. PMID: 33323389.
149. Pilié PG, George A and **Yap TA**. Patient Selection Biomarker Strategies for PARP Inhibitor Therapy. *Ann Oncol* 31(12):1603-1605, 12/2020. e-Pub 10/2020. PMID: 33011228.
150. Collins DC, Sundar R, Constantidinou A, Dolling D, **Yap TA**, Popat S, O'Brien ME, Banerji U, de Bono JS, Lopez JS, Tunariu N, Minchom A. Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. *BMC Cancer* 20(1):1210, 12/2020. PMCID: PMCPMC7724793.
151. Coleman N, Zhang B, Byers LA and **Yap TA**. The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response. *British Journal of Cancer*, 12/2020. PMID: 33328609.
152. Park M, Liu S, **Yap TA**, Yuan Y. Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials. *JAMA Netw Open* 4(2), 2/2021. PMCID: PMCPMC7890531.
153. **Yap TA**, Johnson A, Meric-Bernstam F. Precision Medicine in Oncology - Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations. *JAMA Oncol*, 2/2021. PMID: 33630035.
154. Majd NK, **Yap TA**, Koul D, Balasubramaniyan V, Li X, Khan S, Gandy KS, Yung WKA, de Groot JF. The promise of DNA damage response inhibitors for the treatment of glioblastoma. *Neurooncol Adv*. 3(1), 2/2021. PMCID: PMCPMC7954093.
155. Hedge A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Ileana Dumbrava EE, **Yap TA**, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Summer E, Zain H, Nguyen D, Nguyen LM, Rajakshe K, Curran MA, Hong DS. A Phase I Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. *Clinical Cancer Research*, 3/2021. PMID: 33771853.
156. Collins DC, Sundar R, Constantinidou A, Dolling D, **Yap TA**, Popat S, O'Brien ME, Banerji U, de Bono JS, Lopez JS, Tunariu N, Minchom A. Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. *BMC Cancer* 21:245, 3/2021. PMCID: PMCPMC7938531.
157. Huey R, Georg G, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Pant S, **Yap TA**, Rodon Ahnert J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. *Journal of Clinical Oncology*, 3/2021. PMID: 33783054.
158. **Yap TA**, Siu LL, Calvo E, Lolkema MP, LoRusso PM, Soria J, Plummer R, de Bono JS, Tabernero J, Banerji U. SARS-CoV-2 vaccination and phase 1 cancer clinical trials. *Lancet Oncol* 22(3):298-301, 3/2021. PMCID: PMCPMC7906739.

159. Jiang L, Li R, Yan F, **Yap TA**, Yuan Y. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy. *Contemporary Clinical Trials* 104, 3/2021. PMID: 33711459.
160. **Yap TA**, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of Immunotherapy Combination Strategies in Cancer. *Cancer Discovery* 11:1-30, 4/2021. PMID: 33811048.
161. Shapiro GI, Wesolowski R, Devoe C, Lord S, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R and **Yap TA**. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. *Br J Cancer*. e-Pub 5/2021. PMID: 34040174.
162. Yam C, Ma BBY and **Yap TA**. Global Implementation of Precision Oncology. *JCO Precision Oncology*. 2021 May 18;5:PO.21.00001. doi: 10.1200/PO.21.00001. PMID: 34250385
163. **Yap TA**, Nakagawa K, Fujimoto N, Kuribayashi K, Guren TK, Calabrò L, Shapira-Frommer R, Gao B, Kao S, Matos I, Planchard D, Chatterjee A, Jin F, Norwood K, Kindler HL. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. *Lancet Respir Med* 9(6):613-621, 6/2021. e-Pub 4/2021. PMID: 33836153.
164. Pham MM, Ngoi NYL, Peng G, Tan DSP and **Yap TA**. Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. *Trends in Cancer*. 2021 Jun 19:S2405-8033(21)00105-9. PMID: 34158277
165. Tang Z, Pilie PG, Geng C, Manyam GC, Yang G, Park S, Wang D, Peng S, Wu C, Peng G, **Yap TA**, Corn PG, Broom BM, Thompson TC. ATR inhibitor-induced CDK1-SPOP axis destabilizes PD-L1 and enhances cytotoxicity in prostate cancer. *Clin Cancer Res*. 2021 Jun 24:clincanres.1010.2021. doi: 10.1158/1078-0432.CCR-21-1010. PMID: 34168048
166. Jhaveri K, Burris Rd HA, **Yap TA**, Hamilton E, Rugo HS, Goldman JW, Dann S, Liu F, Wong GY, Krupka H, Shapiro GI. The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. *Expert Rev Anticancer Therapeutics*. 2021 Jun 28. doi: 10.1080/14737140.2021.1944109. PMID: 34176404
167. Ngoi NYL, Pham MM, Tan DSP and **Yap TA**. Targeting the replication stress response through synthetic lethal strategies in cancer medicine. *Trends in Cancer*. 2021 Jun 29:S2405-8033(21)00123-0. doi: 10.1016/j.trecan.2021.06.002. PMID: 34215565
168. Evans KW, Moulder-Thompson S, Yuca E, Scott S, Zhao M, Paez Arango N, Cruz Pico CX, Saridogan T, Shariati M, Class CA, Bristow CA, Vellano CP, Zheng X, Gonzalez-Angulo AM, Su X, Tapia C, Chen K, Akcakanat A, Lim B, Tripathy D, **Yap TA**, Di Francesco ME, Draetta GF, Jones P, Heffernan TP, Marszalek JR, Meric-Bernstam F. Oxidative Phosphorylation is a Metabolic

- Vulnerability in Chemotherapy Resistant Triple Negative Breast Cancer. *Cancer Research*. In press 2021.
169. Hobbs EA, Litton JK and **Yap TA**. Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer. *Expert Opinion on Pharmacotherapy*. In press 2021.
170. Do KT, Chow LQM, Reckamp KL, Sanborn RE, Burris H, Robert F, Camidge DR, Steuer CE, Strickler JH, Weise A, Specht JM, Gutierrez M, Haughney PC, Hengel S, Derleth CL and **Yap TA**. First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors. *Oncologist*. In press 2021.
171. **Yap TA**, Vieito M, Baldini C, Sepúlveda Sánchez JM, Kondo S, Simonelli M, Cosman R, van der Westhuizen A, Atkinson V, Carpentier AF, Löhr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, Man M, Gandhi L, Avsar E, Melisi D. First-In-Human Phase I Study of a Next-Generation, Oral, Transforming Growth Factor-Beta Receptor 1 (TGF- $\beta$ R1) Inhibitor, LY3200882 in Patients with Advanced Cancer. *Clinical Cancer Research*, In Press 2021.
172. **Yap TA**, Krebs MG, Postel-Vinay, El-Khouiery A, Soria J-C, Lopez J, Berges A, Cheung SYA, Arana II, Goldwin, Felicetti B, Jones GN, Lau A, Frewer P, Pierce AJ, Clack G, Stephens C, Smith SA, Dean E, Hollingsworth SJ. Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a Phase I study. *Clinical Cancer Research*, In Press 2021.
-